Psychedelic Succeeds as Quick Depression Fix in Early Trial

(MedPage Today) -- An investigational N,N-dimethyltryptamine treatment -- commonly known as the hallucinogen DMT -- achieved the primary endpoint in a phase IIa trial for major depressive disorder (MDD), developer Small Pharma announced. Paired...
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news